Kanegafuchi Kagaku Kogyo Kabushiki Kaisha

Kaneka Corporation

Kanegafuchi Chemical Industry Co., Ltd.

Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

Activbiotics Pharma, LLC

Takayoshi Hidaka

Kazunori Hosoe

Ikuo Katsumi

Kiyoshi Watanabe

Kenji Fujii

Yutaka Ariki

Taizo Kawabe

Tadayoshi Shiraishi

Keiji Kameyama

Naohiro Imai

Takeshi Domoto

Yoshio Shimada

Katsuji Yamashita

Masaji Kawatsu

Kozo Yamamoto

Yoshiaki Yano

Toshiaki Miwa

Toshiaki Yamashita

Yoshihide Fuse

Hideyuki Kishida

Tatsumasa Mae

Hideo Kondo

Hamao Umezawa

Tomio Takeuchi

Masaaki Ishizuka

Souichi Morikawa

Shigeki Masuda

Naoko Yasuhara

Yoji Hisada

Takehiko Ohfuji

Y Pomeranz

Kazunoro Hosoe

Kazuyuki Takeo

Tamiji Fujimoto

George Todaro

Ribhi M Shawar

Yoshitomo Sakamoto

Noriyuki Naoi

To maintain physical fitness and health of middle-aged and older persons living in the threshold of the aging society, the present invention provides a fatigue reducing agent which is highly effective for preventing and reducing fatigue, wherein the agent is made of a composition of substances that are very safe so that long-term administration is possible. A composition containing reduced coenzyme Q was found to be effective for preventing and reducing fatigue, including muscle fatigue. Since the fatigue reducing effect of the composition of the present invention is seen not only in young rats but also more pronounced in aged rats, the present invention can provide the fatigue reducing agent which is very useful, especially, for middle-aged and older persons as well as for young people.

Fatigue reducing agent

The present invention relates to the supply of coenzyme Q which is highly useful in maintaining human health, and provides a method and preparations whereby coenzyme Q can be efficiently supplied to patients having difficulties in oral administration, aged having swallowing difficulties and patients with diseases caused by topical disorders. It is found that the coenzyme Q concentration in the blood or topical mucosae can be elevated by using a composition for transmucosal administration containing oxidized coenzyme Q and/or reduced coenzyme Q as the active ingredient, wherein the total content of the oxidized coenzyme Q and the reduced coenzyme Q amounts to 0.0001 to 99% by weight of the whole composition.

Composition for transmucosal administration containing conenzyme Q as the active ingredient

The present invention provides a reduced coenzyme Q-containing solution capable of being retained more stably against oxidation, by using a reduced coenzyme Q which is hydrophobic and susceptible to oxidation and thus unstable. The aqueous solution containing a reduced coenzyme Q obtained in the present invention is a solution containing a reduced coenzyme Q and an antioxidant such as vitamin C and/or a chelating agent such as ethylenediaminetetraacetic acid.

Stabilized compositions of aqueous reduced coenzyme Q solution

The present invention provides an antioxidative composition with high safety, which is capable of lessening oxidative stress due to active oxygen species, free radicals, or the like in vivo, thereby preventing the occurrence or worsening of a disease. It was confirmed that by using a composition containing oxidized coenzyme Q and/or reduced coenzyme Q, the amount of urinary 8-hydroxydeoxyquanosine can be decreased in normal or diabetic animals. Also, in histopathological research of the spleens of diabetic rats, it was confirmed that spleen tissue denaturation caused by oxidative stress can be prevented. It was thus found that oxidative stress in vivo can be lessened. According to the present invention, oxidative stress in vivo can be lessened by using a composition containing coenzyme Q as an active ingredient.

Compositions for lessening oxidative stress

The present invention has for its object to provide a method and a composition for achieving a more efficient recovery of the antioxidant activity of plasma LDL, or even augmentation thereof, which has been depressed by the use of an antihyperlipidemic or cholesterol-lowering drug to thereby insure a potentiated antiarteriosclerotic efficacy. A method for inhibiting arteriosclerosis, which comprises using a combination of a cholesterol-lowering agent and a reduced coenzyme Qrepresented by the following formula (1), and a composition for inhibiting arteriosclerosis containing both a cholesterol-lowering agent and said reduced coenzyme Q.

Method and composition for inhibiting arteriosclerosis

Antibacterial compositions comprising (1) a rifamycin derivative represented by the formula (I) or its physiologically acceptable salt, and (2) a proton pump inhibitor (a) or a bismuth preparation (b) wherein the components (1) and (2) are used in such amounts as producing a synergistic effect against drugs and remedies for digestive organ diseases which contain the antibacterial compositions, process for producing them, and pharmaceutical preparations related to the antibacterial compositions. The compositions can be administered to patients with digestive diseases caused by infection of in a smaller dose and at a lower administration frequency as compared with conventional remedies.

Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith

The present invention has for its object to provide a medicinal composition comprising coenzyme Q,as an active ingredient, which composition features an enhanced absorption after oral administration. The present invention is directed to a medicinal composition comprising coenzyme Q,as an active ingredient with the reduced form of coenzyme Q,accounting for more than 20 weight % of said coenzyme Q,.

Pharmaceutical composition comprising coenzyme Q10

The present invention has its object to provide an antihypercholesterolemic or antihyperlipidemic agent, hence a therapeutic and prophylactic drug for arteriosclerosis, which is safer and more potent in cholesterol-lowering action than the hitherto-available drugs. A cholesterol-lowering composition comprising a coenzyme Q of the following formula (I) or a reduced coenzyme Q of the following formula (II) as an active ingredient: ##STR1## wherein n represents an integer of 6 to 11

Cholesterol-lowering composition

A method for treatment of diseases caused by Chlamydia infection is disclosed comprising administering a rifamycin of the formula (I): ##STR1## wherein R.sup.1 is hydrogen atom or acetyl, and X is oxygen, sulfur or a group NR, in which R is hydrogen, an alkyl group having 1 to 7 carbon atoms or a group of the formula (II): ##STR2## in which n is an integer of 1 to 3; or a physiologically acceptable salt thereof.

Method for treating chlamydia infectious diseases by rifamycin derivative

The present invention provides an ophthalmic composition comprising a sleep inducing substance or a sleep inhibiting substance, and the sleep inducing substance or the sleep inhibiting substance is derived from an organism. Thus, the invention provides an ophthalmic composition comprising a sleep adjusting substance which normalizes irregularity of the rhythm of sleep and a liquid ophthalmic medicament comprising the composition, the composition and the medicament being safe and obtainable by anyone, and a method for regulating the rhythm of sleep comprising instilling the ophthalmic medicament including the sleep adjusting substance to an individual.

Ophthalmic composition comprising a sleep adjusting substance

The present invention is directed to a sticky composition for medical use comprising a tackifier resin and an oxyalkylene polymer having a silicon-containing group which can be crosslinked by forming a siloxane bond, wherein silicon atom thereof is bound with a hydroxyl group or hydrolytic group, and to a transdermal drug delivery preparation incorporating said sticky composition as a drug carrier. The sticky composition of the present invention possesses excellent adhesive properties, very low skin irritancy and good compatibility with the site of plastering and thus perform as a very safe and effective medical adhesive. The transdermal drug delivery preparation of the present invention offers excellent drug release from the sticky composition.

Adhesive composition for medical use

Method for producing microgranulated particle

Cognition enhancing quinuclidine compound

The present invention is directed to a stable pharmaceutical composition wherein the absorbability of a lipophilic drug which is insoluble or practically insoluble in water or another drug such as a bioactive peptide in oral administration has been improved to such extent that a high level of blood concentration can be retained, and to a method for producing such a stable pharmaceutical composition. The pharmaceutical composition of the present invention offers improvements in the absorbability, for example, a high level of blood concentration can be retained for a long time in oral administration because it is highly resistant to lipase. Also, the pharmaceutical composition is highly safe because the emulsifier used is derived from mammalian milk.

Stable pharmaceutical composition and method for its production

Phenoxybenzene derivative

Growing community of inventors

Kobe, Japan

Takayoshi Hidaka